Gem-CHOP: A randomized phase II study of gemcitabine combined with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] with or without rituximab in untreated aggressive non-Hodgkin's lymphoma.

Trial Profile

Gem-CHOP: A randomized phase II study of gemcitabine combined with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] with or without rituximab in untreated aggressive non-Hodgkin's lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Gemcitabine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2011 Primary endpoint 'Complete-clinical-response-rate' has not been met.
    • 18 Feb 2009 Results have been reported at the 50th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Mar 2007 Status changed from recruiting to in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top